The c-Fms inhibitor 2 is primarily utilized in research and development within the field of oncology. It is specifically designed to target and inhibit the c-Fms kinase, which plays a crucial role in the survival and proliferation of certain cancer cells, particularly those involved in leukemia and solid tumors. By blocking this kinase, the inhibitor helps to disrupt the signaling pathways that promote tumor growth and metastasis. This makes it a valuable tool in preclinical studies aimed at understanding cancer mechanisms and evaluating potential therapeutic strategies. Additionally, it is used in the development of targeted therapies that aim to minimize the side effects commonly associated with traditional chemotherapy. Its application extends to the study of tumor-associated macrophages, which are often implicated in tumor progression and immune evasion, providing insights into novel approaches for cancer immunotherapy.